BioSenic, a clinical-stage company, discusses their late-clinical asset JTA-004 for severe knee osteoarthritis. They share data on its safety and efficacy at an international congress. Topics covered include the mechanism of action of JTA-004, attending events, potential administration frequency, other companies working on osteoarthritis, and future steps.